Clinical Trials Logo

Opiate Substitution Treatment clinical trials

View clinical trials related to Opiate Substitution Treatment.

Filter by:
  • None
  • Page 1

NCT ID: NCT05657106 Active, not recruiting - Clinical trials for Opioid-Related Disorders

Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk

Start date: March 6, 2023
Phase: N/A
Study type: Interventional

This study will test the effectiveness, implementation outcomes, and cost effectiveness of a community-tailored, harm reduction kiosk in reducing HIV, hepatitis C, and overdose risk behavior in rural Appalachia. The proposed project will take place in two counties in Appalachian Kentucky, an epicenter for the intertwined national crises of injection drug use, overdoses, and hepatitis C.

NCT ID: NCT05336188 Enrolling by invitation - Clinical trials for Opioid-Related Disorders

Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder

Start date: May 16, 2023
Phase: Phase 2
Study type: Interventional

The proposed clinical trial would evaluate the use of smartphone applications ("apps", which have well-established efficacy in reducing cigarette and alcohol use) to prevent relapse among patients receiving medication-assisted treatment for opioid use disorder. In addition to standard app-based self-monitoring of drug use and personalized feedback, project innovation is enhanced by the proposed use of location-tracking technology for targeted, personalized intervention when participants enter self-identified areas of high risk for relapse. Furthermore, the proposed sub-study would use longitudinal functional neuroimaging to elucidate the brain-cognition relationships underlying individual differences in treatment outcomes, offering broad significance for understanding and enhancing the efficacy of this and other app-based interventions.

NCT ID: NCT05164549 Completed - Clinical trials for Opiate Substitution Treatment

Extended-release Pharmacotherapy for Opioid Use Disorder

EXPO
Start date: August 6, 2019
Phase: Phase 3
Study type: Interventional

The primary objective is a clinical superiority effectiveness contrast to standard of care. Reported following SPIRIT and CONSORT standards, the study will determine whether extended-release injectable depot Buprenorphine (XR-Bup) maintenance therapy for OUD over six months is clinically superior to standard-of-care, oral medication (sublingual Buprenorphine [SL-Bup] or oral methadone [Met]; together: Bup/Met)

NCT ID: NCT04199728 Completed - Clinical trials for Opioid-Related Disorders

Use of a GLP-1R Agonist to Treat Opioid Use Disorder

Start date: October 18, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This research is being done to find out if liraglutide (brand name is Saxenda®) can safely and effectively reduce craving for opioids in patients with opioid use disorder, a primary factor contributing to early relapse.

NCT ID: NCT04162184 Active, not recruiting - Clinical trials for Substance-Related Disorders

Increasing Linkage to Family Planning Care for Individuals With Substance Use Disorder

Start date: December 16, 2019
Phase: N/A
Study type: Interventional

This study will utilize mixed methods to develop and assess the feasibility and acceptability of a health educator intervention designed to connect patients in recovery from substance use disorder to reproductive health education and services.

NCT ID: NCT03948464 Terminated - Clinical trials for Opioid-Related Disorders

Slow-Release Oral Morphine for the Treatment of Opioid Use Disorder

pRESTO
Start date: December 6, 2019
Phase: Phase 3
Study type: Interventional

This is a non-inferiority randomized clinical trial that will compare slow release oral morphine vs methadone as a second line oral treatment for opioid use disorder.

NCT ID: NCT02496403 Completed - Clinical trials for Opiate Substitution Treatment

Buprenorphine and Substance Abuse Services for Prescription Opioid Dependence

Start date: December 2015
Phase: N/A
Study type: Interventional

This is a randomized trial of two group-based models of care for buprenorphine/naloxone (bup/nx) patients in Substance Use (SU) specialty treatment: Standard Medical Management (SMM) and Intensive Outpatient Treatment (IOT). The setting is a large outpatient SU treatment program, where a medical management model of care has not been empirically tested with bup/nx patients, and where a high prevalence of patients with co-occurring psychiatric and medical co-morbidities are treated. SSM includes brief weekly group-based visits consistent with previously studied medical models, and is drawn from primary care bup/nx research. IOT is a predominant model of care in specialty treatment, and incorporates psychosocial support, 12-step, educational and relapse-prevention based approaches. The investigators will recruit 300 adult patients inducted onto bup/nx, randomize them to either SMM or IOT, and conduct telephone follow-up interviews at 6 and 12 months. Study investigators will examine the impact of these treatment approaches on 90-day bup/nx adherence, opioid and SU abstinence, quality of life, and health care and societal costs. Further, investigators will examine whether the effect of IOT versus SMM on adherence and SU treatment outcomes is greater for those with medical or psychiatric co-morbidities. This innovative approach includes a focus on complex patients with psychiatric and medical co-morbidities in specialty care, adapting a care model previously only tested in primary care, a 12-month follow-up, no research-forced medication taper, an examination of health care and societal costs, and a combination of patient self-report and electronic medical record data. Through this approach, the proposed study will yield critically important findings on how best to treat complex prescription opioid dependent patients with an integrative behavioral services and medication treatment model in SU treatment.